CD43 is an adverse prognostic factor in newly diagnosed multiple myeloma

References

• Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43(6):676–681.
   PubMed Web of Science ®Google Scholar
• Mateos M-V, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28(13):2259–2266.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–1128.
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420.
   PubMed Web of Science ®Google Scholar
• Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842–854.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–2869.
   PubMed Web of Science ®Google Scholar
• Rosenstein Y, Santana A, Pedraza-Alva G. CD43, a molecule with multiple functions. Immunol Res. 1999;20(3):89–99.
   PubMedGoogle Scholar
• Inui M, Hirota S, Hirano K, et al. Human CD43+ B cells are closely related not only to memory B cells phenotypically but also to plasmablasts developmentally in healthy individuals. Int Immunol. 2015;27(7):345–355.
   PubMed Web of Science ®Google Scholar
• Sorigue M. CD43 in the malignant flow cytometry laboratory in 2020. Expert Rev Hematol. 2020; 14(1):123–136
   Web of Science ®Google Scholar
• Matsumoto M, Atarashi K, Umemoto E, et al. CD43 functions as a ligand for E-Selectin on activated T cells. J Immunol. 2005;175(12):8042–8050.
   PubMed Web of Science ®Google Scholar
• Gillissen MA, de Jong G, Kedde M, et al. Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in mice. Blood Adv. 2017;1(19):1551–1564.
   PubMed Web of Science ®Google Scholar
• Caracciolo D, Riillo C, Ballerini A, et al. Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia. J Immunother Cancer. 2021;9(2):e002026.
   PubMed Web of Science ®Google Scholar
• Ma XB, Zheng Y, Yuan HP, et al. CD43 expression in diffuse large B-cell lymphoma, not otherwise specified: CD43 is a marker of adverse prognosis. Hum Pathol. 2015;46(4):593–599.
   PubMed Web of Science ®Google Scholar
• Salem DA, Scott D, McCoy CS, et al. Differential expression of CD43, CD81, and CD200 in classic versus variant hairy cell leukemia. Cytometry. 2019;96(4):275–282.
   PubMedGoogle Scholar
• Falay M, Afacan Öztürk B, Güneş K, et al. The role of CD200 and CD43 expression in differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma. Turk J Haematol. 2018;35(2):94–98.
   PubMed Web of Science ®Google Scholar
• Tuccillo FM, Palmieri C, Fiume G, et al. Cancer-associated CD43 glycoforms as target of immunotherapy. Mol Cancer Ther. 2014;13(3):752–762.
   PubMed Web of Science ®Google Scholar
• Mitrovic Z, Iqbal J, Fu K, et al. CD43 expression is associated with inferior survival in the non-germinal Centre B-cell subgroup of diffuse large B-cell lymphoma. Br J Haematol. 2013;162(1):87–92.
   PubMed Web of Science ®Google Scholar
• de Laurentiis A, Gaspari M, Palmieri C, et al. Mass spectrometry-based identification of the tumor antigen UN1 as the transmembrane CD43 sialoglycoprotein. Mol Cell Proteomics. 2011;10(5):M111 007898.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548.
   PubMed Web of Science ®Google Scholar
• Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Shigeta A, Furukawa Y, et al. CD43 collaborates with P-selectin glycoprotein ligand-1 to mediate E-selectin-dependent T cell migration into inflamed skin. J Immunol. 2007;178(4):2499–2506.
   PubMed Web of Science ®Google Scholar
• Rosenstein Y, Park JK, Hahn WC, et al. CD43, a molecule defective in Wiskott-Aldrich syndrome, binds ICAM-1. Nature. 1991;354(6350):233–235.
   PubMed Web of Science ®Google Scholar
• Tuccillo FM, de Laurentiis A, Palmieri C, et al. Aberrant glycosylation as biomarker for cancer: focus on CD43. Biomed Res Int. 2014;2014:742831.
   PubMed Web of Science ®Google Scholar
• Jimi E, Phillips RJ, Rincon M, et al. Activation of NF-kappaB promotes the transition of large, CD43+ pre-B cells to small, CD43- pre-B cells. Int Immunol. 2005;17(6):815–825.
   PubMed Web of Science ®Google Scholar
• Balikova A, Jääger K, Viil J, et al. Leukocyte marker CD43 promotes cell growth in co-operation with β-catenin in non-hematopoietic cancer cells. Int J Oncol. 2012;41(1):299–309.
   PubMed Web of Science ®Google Scholar
• Park WS, Kim HJ, Lee GK, et al. Anti-adhesive functions of CD43 expressed on Colon carcinoma cells through the modulation of integrins. Exp Mol Pathol. 2012;92(1):82–89.
   PubMed Web of Science ®Google Scholar
• Nonomura C, Kikuchi J, Kiyokawa N, et al. CD43, but not P-selectin glycoprotein ligand-1, functions as an E-selectin counter-receptor in human pre-B-cell leukemia NALL-1. Cancer Res. 2008;68(3):790–799.
   PubMed Web of Science ®Google Scholar
• Mitrovic Z, Ilic I, Nola M, et al. CD43 expression is an adverse prognostic factor in diffuse large B-Cell lymphoma. Clin Lymphoma Myeloma. 2009;9(2):133–137.
   PubMedGoogle Scholar
• Cermak L, Simova S, Pintzas A, et al. Molecular mechanisms involved in CD43-mediated apoptosis of TF-1 cells. J Biol Chem. 2002;277(10):7955–7961.
   PubMed Web of Science ®Google Scholar
• Kadaja-Saarepuu L, Laos S, Jaager K, et al. CD43 promotes cell growth and helps to evade FAS-mediated apoptosis in non-hematopoietic cancer cells lacking the tumor suppressors p53 or ARF. Oncogene. 2008;27(12):1705–1715.
   PubMed Web of Science ®Google Scholar